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In rat models, CD4+CD25+ T regulatory cells (Treg) play a key role in the induction and
maintenance of antigen-specific transplant tolerance, especially in DA rats with PVG car-
diac allografts (1, 2). We have previously described generation of alloantigen-specific Treg
(Ts1), by culture of naïve natural CD4+CD25+ Treg (nTreg) with specific alloantigen and IL-2
for 4 days. These cells express mRNA for IFN-γ receptor (ifngr ) and suppress donor but
not third party cardiac allograft rejection mediated by alloreactive CD4+ T cells at ratios of
<1:10. Here, we show thatTs1 also expressed the IL-12p70 specific receptor (il-12rβ2) and
that rIL-12p70 can induce their proliferation. Ts1 cells re-cultured with rIL-12p70 alone or
rIL-12p70 and recombinant interleukin-2 (rIL-2), suppressed proliferation of CD4+ T cells in
mixed lymphocyte culture at <1:1024, whereasTs1 cells re-cultured with rIL-2 and alloanti-
gen only suppressed at 1:32–64. The rIL-12p70 alloactivated Ts1 cells markedly delayed
PVG, but not third party Lewis, cardiac allograft rejection in normal DA recipients.Ts1 cells
re-cultured for 4 days with rIL-12p70 alone, but not those re-cultured with rIL-12p70 and
rIL-2, expressed more il-12rβ2, t-bet, and ifn-γ, and continued to express the markers of
Ts1 cells, foxp3, ifngr, and il-5 indicating Th1-like Treg were induced. Ts1 cells re-cultured
with rIL-2 and alloantigen remained of theTs1 phenotype and did not suppress cardiac graft
rejection in normal DA rats. We induced highly suppressive Th1-like Treg from naïve nTreg
in 7 days by culture with alloantigen, first with rIL-2 then with rIL-12p70. These Th1-like Treg
delayed specific donor allograft rejection demonstrating therapeutic potential.
Keywords:T regulatory cells, antigen-specificTreg,Th1-likeTreg, allograft rejection, IL-12p70
INTRODUCTION
Antigen-specific CD4+CD25+ T regulatory cells (Treg) mediate
transplant tolerance (3–5) and can protect against autoimmunity
(6). Natural CD4+CD25+ Treg (nTreg) prevent autoimmunity (7)
and contribute to the induction of transplant tolerance (8). How-
ever,nTreg mediated suppression is not antigen-specific (9,10) and
requires high ratios, usually>1:1 of nTreg:effector CD4+ T cells to
inhibit organ allograft rejection (2, 8) or graft versus host disease
(GVHD) (11). This required ratio is much higher than the 1:10
or less that is in peripheral lymphoid tissues of normal and trans-
plant tolerant animals (4). There is tight homeostatic control of
the ratio of CD4+CD25+ T cells to CD4+CD25− T cells in periph-
eral lymphoid tissues, thus alloantigen-specific CD4+CD25+ Treg
maintain tolerance to the allograft at ratios of <1:10 (4). Thus
antigen-specific Treg suppress at ratios of <1:10 and would need
fewer cells to induce tolerance than with nTreg.
nTreg in vitro can be massively expanded using current cul-
ture techniques with IL-2 and stimulation with anti-CD3 alone
or combined with anti-CD28 monoclonal antibodies (mAb) (12),
but these Treg only suppress at ratios of >1:1. Thus, extremely
large numbers of nTreg are required in vivo to prevent allograft
rejection and GVHD in unmodified recipients (13). The num-
ber of expanded nTreg required is so high it may be impossible
to achieve in humans (13). Methods that induce more potent
antigen-specific Treg, that can suppress at lower ratios and thus
require fewer Treg would be desirable.
We previously reported that nTreg cultured with recombi-
nant interleukin-2 (rIL-2) and alloantigen produce alloantigen-
specific Treg that suppress in vitro and in vivo (2, 14–16). These
antigen-specific Treg, suppress in vivo at lower ratios of 1:10.
Our earlier studies show CD4+ T cells that transfer transplant
tolerance are short lived in vitro (3, 17, 18) but their suppressive
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potential is preserved by culture with donor specific alloantigen
and lymphocyte derived cytokines (18). The specific cytokines
required are not completely characterized, but IL-2 (18) or IL-4
(19) alone are not sufficient to fully maintain CD4+ Treg that
transfer transplant tolerance (18). This suggests that induction
and expansion of antigen-specific Treg, that can maintain trans-
plant tolerance, may depend on cytokines other than IL-2 or
IL-4 long term, albeit there initial activation requires either IL-2
or IL-4.
We have previously reported that short term cultures of nTreg
with either rIL-2 or rIL-4 and alloantigen for 3–4 days induce
alloantigen-specific Treg that inhibit specific donor but not third
party fully allogeneic heart graft rejection at ratios of 1:10 (2).
They also inhibit proliferation of CD4+ T cells to specific donor
more than to third party in mixed lymphocyte culture (MLC) (2).
Culture of nTreg with rIL-2 and alloantigen induced expression
of IFN-γ receptor (ifngr) and il-5, but reduced ifn-γ expression
(2). As the abbreviation Tr1 had been designated to IL-10 acti-
vated Treg, we named these rIL-2 activated Treg as Ts1 that express
receptors for Th1 cytokines (2). Activation of nTreg with rIL-4
and alloantigen generated activated Tregs expressing il-5rα, a Th2
cytokine receptor; not ifngr, and were named Ts2 (2).
The pathways by which nTreg may be activated by Th1 or
Th2 cytokines to produce antigen-specific Treg, has recently been
reviewed (1). There is increasing evidence that Treg function could
be influenced by Th1 cytokines, other that IL-2. Activated Treg
express ifngr (20) and the receptor for IL-12p70 (il-12rβ2) (21).
IL-12Rβ2−/− mice develop more rapid and severe autoimmune
disease than wild-type (22) due to reduced CD4+CD25+ Treg
activity (21). In uncontrolled Th1 responses, IFN-γ and IL-12p70
induce Treg to express t-bet and ifn-γ while they continue to
express foxp3 and suppress (23, 24). These rIL-12p70 activated
Treg are called Th1-like Treg, because they express the Th1 tran-
scription factor t-bet and the Th1 cytokine ifn-γ as well as foxp3
but do not produce IL-2. Induction of Th1-like Treg by IL-12p70
does not occur in the presence of IL-2 (21, 25). Th1-like Treg
have been described in patients with multiple sclerosis (26) and
renal transplants (27). The precise role of Th1-like Treg is not
understood.
Here we described that Ts1 cells also expressed mRNA for il-
12rβ2, the specific receptor for IL-12p70, and their culture with
rIL-12p70 and alloantigen resulted in their proliferation and fur-
ther activation into Th1-like Treg, expressing t-bet, ifn-γ and
foxp3, ifngr and il-12rβ2. These Th1-like Treg were much more
potent than nTreg or Ts1 in suppressing CD4+ T cell responses
to alloantigen in vitro and in vivo. We have selectively expanded
alloantigen-specific Treg, a situation that will have only a minority
of cells growing, therefore there were lower rates of proliferation
than with polyclonal expansion of nTreg.
MATERIALS AND METHODS
ANIMALS
DA (RT1a), PVG (RT1c), and Lewis (RT-1l) rats were bred and
maintained in the animal house, Liverpool Hospital. Heterotopic
heart grafts were performed as described (28). Experiments were
approved by the Animal Ethics Committee of the University of
New South Wales.
MONOCLONAL ANTIBODIES AND CYTOKINES
Anti-rat mAb used were W3/25 (CD4), MRCOx8 (CD8),
MRCOx39 (CD25), MRCOx33 (CD45RA), MRCOx6 (class II
MHC) (BD-PharMingen, San Diego, CA, USA), and FITC anti-
mouse/rat Foxp3 (eBioscience, San Diego, CA, USA). Subsets of
T cells were identified by indirect immunofluorescence staining
and enumerated by gating the whole lymphocyte population on a
FACScan, as described (9).
Rat recombinant, rIL-12p70, rIL-12p40, and rIL-2 were pre-
pared and assayed as described (29). Briefly, rat IL-12p35 and
IL-12p40 were cloned from rat spleen cells and transfected alone or
together into Chinese Hamster Ovary cells (CHOK1). rIL-12p70
was produced from CHOK1 cells lines transfected with both p35
and p40, as described (29). Cytokines were produced from sta-
bly transfected CHOK1 cells grown to confluence in DMEM-F12
medium (GIBCO, Life Technology, Grand Island, NY, USA) with
10% FCS (Trace Biosciences, Castle Hill, NSW, Australia), then
washed and re-cultured in serum free medium. After 4–5 days, the
medium was harvested and assayed for capacity to promote prolif-
eration of IL-2/ConA activated rat spleen cells in culture for 4 days.
One unit was defined as the cytokine that induced 50% maximum
proliferation (29). rIL-4 transfected line (30) was a kind gift of
Dr. Neil Barclay (School of Pathology, Oxford, UK) and was pro-
duced as supernatant from transfected CHOK1 cells lines grown
in serum free medium and assessed in a bioassay for it ability to
induce class II MHC on B cells, as described (2, 29).
PREPARATION OF T CELL SUBSETS
Lymph nodes and spleen cells from naïve DA rats were depleted of
CD8+ T and B cells using mAb MRCOx8 (CD8) and MRCOx33
(CD45RA) and an indirect panning technique, as described (31).
The CD4+CD25+ Treg population was prepared using PE conju-
gated MRCOx39 and mouse anti-PE microbeads (Miltenyi, Ber-
gisch Gladbach, Germany) before eluting through a LS MACS
column (Miltenyi), as described (2, 8, 9). The cells were 98–99%
CD4+, 85–95% CD25+, and approximately 80% Foxp3+.
CULTURE OF CD4+CD25+ T CELLS TO INDUCE ALLOANTIGEN-SPECIFIC
Treg (Ts1)
Cell culture medium used was RPMI 1640 (GIBCO) supple-
mented with 100 ng/ml penicillin, 100 U/ml streptomycin (Glaxo,
Boronia, VIC, Australia), 2 mM l-glutamine, 5× 10−5 M 2-
mercaptoethanol (Sigma), and 20% Lewis rat serum. Stimulator
cells were thymus cells of DA, PVG, or third party Lewis rats
irradiated in vitro with 9 Gy, as described (32). Stimulator cells
had <1% lymphocytes and background levels of mRNA for T
cell cytokine (32). MLCs with naïve DA CD4+, CD4+CD25−, or
CD4+CD25+ T cells were performed, as described (9), that had
either no cytokine, rIL-2 (200 units/ml) or rIL-4 (200 units/ml)
alone or with rIL-12p70 (20 units/ml). 200 units/ml of rIL-2 or
rIL-4 is the optimal concentration for activation of nTreg (2).
Cultures in U-bottom microtiter plates (Greiner, Frickenhausen,
Germany) had 2× 104 stimulator cells and 105 responder T cells
per well. Six replicate wells were set up for each group.
For bulk cultures, naïve DA CD4+CD25+ Treg (2× 106/ml)
were cultured with irradiated thymus stimulator cells (106/ml)
from PVG rats in 25 cm2 flasks (Greiner). These when cultured for
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3–4 days with rIL-2 or rIL-4 produced Ts1 or Ts2 cells, as described
(2, 9). Ts1 cells were washed and further cultured with new PVG
stimulator cells and rIL-2 alone (200 units/ml), rIL-12p70 alone
(20 units/ml), rIL-2 and rIL-12p70 or rIL-12p40 for 3–4 days. After
3–4 days of culture, cells were assayed by FACS for cell surface
markers, by RT-PCR for cytokine and cytokine receptor expression
and by 3H-thymidine incorporation for cell proliferation assay and
for their ability to inhibit naïve syngeneic CD4+ T or CD4+CD25−
T cell proliferation in MLC, as described (2).
The effects of blocking IFN-γwith the mAb DB-1 (33) (Ucytec,
Utrecht, The Netherlands) at 50µg/ml or iNOS with L-NIL (Sigma
Chemicals, St. Louis, MO, USA) at 0.1 mg/ml on activation of Ts1
cells by rIL-12p70 was examined. DB-1 and L-NIL,at these concen-
trations have no effect on nTreg proliferation in MLC but enhance
proliferation of CD4+CD25− cells showing they block iNOS and
NO production that inhibits cell proliferation (9).
RT-PCR
RNA extraction, cDNA synthesis, and semi-quantitative PCR on
a Rotorgene PCR machine (Corbett Research, Mortlake, NSW,
Australia) were performed as described (2, 32). Known primers
for rat gapdh, il-2, ifn-γ, il-4, il-5 (32, 34), ifngr, il-5rα, foxp3, t-
bet, gata-3 (2), il-12rβ2 (29), and SYBR Green I and HotMaster
Taq polymerase (Eppendorf AG, Hamburg, Germany) or Sen-
siMix DNA kit (Bioline, Alexandria, NSW, Australia) were used
as described (32, 34). Gene copy number was derived from a
standard curve run in parallel and normalized against gapdh as
described (2).
SUPPRESSOR ASSAY
Microcultures in U -bottom micro-titer plates (Linbro, Flow Labs,
VA, USA) were prepared with serial dilutions of Treg. To each well
2× 104 irradiated thymus stimulator cells either from syngeneic
DA, specific donor PVG or third party Lewis and 105 DA responder
naïve CD4+ T cells or naïve CD4+CD25− T cells, were added in
a final total volume of 200µl as previously described (9) (four to
six replicate wells/treatment). Proliferation was measured by 3H-
thymidine incorporation at day 4 as described (9). In rat MLC,
CD4+ T cell proliferation is usually 3–10× 103 cpm, and autolo-
gous responses have low backgrounds of 2–3× 103 cpm, whereas
CD4+CD25− T cells have higher responses to self and alloantigen,
as no nTreg cells are present (9).
CARDIAC ALLOGRAFTS
Heterotopic PVG or Lewis hearts were grafted into naïve DA rats
as described (28). Graft function was monitored by palpation,
as described (2). In DA rats, prolonged graft survival is easier
to induce with PVG (35) or Lewis (36) organ allografts than with
other strains (37). Thus, Lewis grafts are an appropriate third party
control. On day 3 post-transplant, recipient rats received 5× 106
Treg that had been activated with PVG stimulators and rIL-2 for
3 days followed by 4 days with PVG stimulators and either rIL-
12p70 or rIL-2. The Treg were given at 3 days post-transplant as
this allows the host response to the allograft to be activated, and the
response to produce cytokines such as IL-12 that may be required
to promote further expansion and survival of the Treg in vivo.
STATISTICAL ANALYSES
Parametric data was expressed as mean± standard deviation and
assessed with a Student’s t -test, while non-parametric data was
assessed with a Wilcoxon Rank Sum test on Statview (Abacus
Concepts, Berkeley, CA, USA). Statistical significance was p< 0.05.
RESULTS
EFFECT OF rIL-12 p70 ON PROLIFERATION OF CD4+CD25+ T CELLS
The bioassay of IL-12p70 tests its ability to promote prolifer-
ation of IL-2 activated T cells (38). As nTreg proliferate with
IL-2, we examined the effects of rIL-12p70 on proliferation of
CD4+CD25+ Treg from DA rats stimulated with PVG alloanti-
gens in presence of rIL-2 or rIL-4 (Figure 1A). Addition of either
rIL-2 or rIL-4, enhanced proliferation of nTreg, as described (6).
rIL-12p70 (20 units/ml) alone had no effect on proliferation but
when added with rIL-2 enhanced proliferation compared to rIL-
2 alone (p< 0.05). Combination of rIL-4 and rIL-12p70 did not
enhance proliferation of nTreg, compared to rIL-4 alone. With
autologous DA stimulator cells, rIL-2 and to a lesser extent rIL-4
induced proliferation of nTreg, but rIL-12p70 had no synergistic
effect with either.
In parallel, we examined the effects of rIL-2 or rIL-4 alone or
with rIL-12p70 on naïve CD4+CD25− T cell proliferation to either
auto- or alloantigen (Figure 1B). For allogeneic stimulators, rIL-
12p70 combined with rIL-2 had a trend to increased proliferation
compared to rIL-2 alone, and had no effect when combined with
rIL-4. Naïve CD4+CD25− T cells’ response to auto-antigen was
enhanced by rIL-2, but not with rIL-4 or rIL-12p70.
EXPRESSION OF il-12rβ2 BY nTREG ACTIVATED BY rIL-2 (Ts1) BUT NOT
rIL-4 (Ts2)
Ts1 and Ts2 cells were generated by activation of nTreg with
alloantigen and rIL-2 or rIL-4 respectively, as described (2). Per-
centage of cells expressing CD25 remained unchanged when cul-
tured with alloantigen and either rIL-2 (Figure 2A) or rIL-4 (data
not shown) (2), and 70–80% of cells expressed Foxp3 (2).
These Ts1 and Ts2 cells were first re-enriched for CD25+ cells to
remove stimulator cells, before mRNA was extracted. Fresh nTreg
did not express il-12rβ2, the specific receptor for IL-12p70. There
was high expression of il-12rβ2 on Ts1 cells (Figure 2B). Minimal
expression of il-12rβ2 was noted in nTreg cultured with autoanti-
gen and rIL-2 and no expression with either auto- or alloantigen
and rIL-4. There was no induction of il-2 with any culture con-
dition (results not shown), suggesting no Th1 cell induction.
These results suggested that within 3–4 days of culture with rIL-
2 and alloantigen, alloantigen-specific activated nTreg expressed
il-12rβ2.
rIL-12 p70 PROMOTED PROLIFERATION OF Ts1 CELLS
Re-culture of Ts1 with the same alloantigen for 4 days with rIL-2,
rIL-12p70, or rIL-12p40 was performed (Figure 2C). With rIL-
12p70 alone, proliferation was induced, though not as great as
with rIL-2 alone. rIL-12p40 did not induce proliferation. Thus,
rIL-12p70 acted as a growth factor for Ts1 cells albeit not as potent
as rIL-2, a polyclonal activator of nTreg. The lesser response with
rIL-12p70 is consistent with promotion of a small subpopulation
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FIGURE 1 | Effect of rIL-12p70 on proliferation of CD4+CD25+ and
CD4+CD25− T cells in MLC supplemented with either rIL-2 or rIL-4.
(A) Effect of rIL-12p70, alone or in combination with either rIL-2 or rIL-4, on
proliferation of (A) CD4+CD25+ T cells and (B) CD4+CD25− T cells from naïve
DA rats stimulated in culture with either self (DA) or allogeneic (PVG)
stimulator cells. These were primary mixed lymphocyte cultures with
proliferation assessed at day 4. The cells were fresh and had not been
cultured before. Addition of rIL-12p70 enhanced proliferation of CD4+CD25+ T
cells to alloantigen, not auto-antigen, in cultures with rIL-2 but not with rIL-4.
rIL-12p70 had no significant effect on proliferation of CD4+CD25− T cells, even
when rIL-2 was present. *Significant differences (p<0.05). Similar results
have been obtained in other experiments.
of alloantigen-activated Treg rather than polyclonal activation of
nTreg (2).
rIL-12p70 ENHANCED REGULATORY ACTIVITY OF Ts1 CELLS
nTreg from DA rats were initially stimulated with rIL-2 and
PVG alloantigen for 3 days to generate Ts1 cells, and were then
re-cultured for 4 days with alloantigen and either rIL-2 alone, rIL-
12p70 alone, or both rIL-2 and rIL-12p70. In all three cultures, a
large proportion was CD25+ (75–83%) compared to>95% in the
starting fresh naïve nTregs. Seventy to eighty percent of the cells
continued to express Foxp3 (Figure 3A), similar to fresh naïve
Treg. After 3 days of culture of nTreg with rIL-2 and alloantigen,
the number of cells recovered was 34–43% of the starting number
of nTreg. After re-culture of Ts1 cells for 4 days with rIL-2 alone
or rIL-2 and rIL-12p70 the yields were 50–100% of the original
cell number. After re-culture of Ts1 cells with rIL-12p70, the yield
was 25–50% of the original Ts1 population. Culture with rIL-
12p70 may select antigen-specific Treg, whereas rIL-2 polyclonally
expands nTreg.
The suppressive ability of these re-cultured Ts1 on naïve
CD4+CD25− T proliferation to specific alloantigen was exam-
ined. This assay had serial dilutions of re-cultured Ts1, with the
same number of stimulator and CD4+CD25− T responder cells in
all wells (Figure 3B). Without allogeneic stimulator cells, suppres-
sion was similar to background proliferation level of CD4+CD25−
T cells. Ts1 cells re-cultured with rIL-2 were unable to suppress at
dilutions greater than 1:32–1:64 (2). In contrast, Ts1 cells cultured
with rIL-12p70 alone or with rIL-2 and rIL-12p70 showed much
enhanced suppressive ability and fully suppressed proliferation of
CD4+CD25− T cells to autologous background levels at 1:256.
In other experiments, suppression of proliferation to background
level was observed until 1:1024. This suppression was not antigen-
specific, however (Figure 3B). In the methods of MLC that we use,
naïve CD4+CD25− T cells have a greater response to auto-antigen
than CD4+ T cell as they lack nTreg. This proliferation to self is
usually over 50% of that to alloantigen, as seen in this assay (9).
Rat CD4+ T cells have lower levels of proliferation in MLC than
humans and mice, thus these responses are normal for rat CD4+
T cells.
CYTOKINE AND CYTOKINE RECEPTOR mRNA EXPRESSION IN Ts1 CELLS
CULTURED WITH rIL-12p70, rIL-2, OR rIL-2 AND rIL-12p70
Ts1 cells were re-cultured for 4 days with alloantigen and rIL-
2 or rIL-12p70 or both rIL-2 and rIL-12p70 before enrichment
with CD25-PE beads to eliminate stimulator cells. mRNA was
extracted and subjected to RT-PCR for cytokine and cytokine
receptor mRNA expression. We compared mRNA from these cells
to mRNA from fresh nTreg and Ts1 cells (Figure 4). Expression of
il-12rβ2 was increased when Ts1 cells were re-cultured with rIL-2
alone or rIL-12p70 alone but markedly reduced when Ts1 cells
were re-cultured with both rIL-2 and rIL-12p70. Ifngr expression
was sustained by culture with IL-2, but was diminished in cultures
with rIL-12p70.
FACS analysis showed Foxp3 expression was maintained after
re-culture of Ts1 cells with rIL-12p70 alone (77% Foxp3+), rIL-
2 alone (66% Foxp3+), and both rIL-2 and rIL-12p70 (70%
Foxp3+).
il-2 was not expressed in any culture conditions (data not
shown), consistent with a Treg population, not a Th1 cell
induction. The Th1 transcription factor t-bet and the Th1 cytokine
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FIGURE 2 | Expression of CD25 and il-12rβ2 and in vitro proliferation in
MLC of naïve CD4+CD25+ T cells. (A) Comparison of naïve CD4+CD25+ T
cells before and after culture with rIL-2 and alloantigen. The majority of
CD4+ T cells expressed CD25 before culture (nTreg) and remained CD25+
post-culture with rIL-2 and alloantigen (Ts1). Replicated in several
experiments. (B) Expression of il-12rβ2 in CD4+CD25+ T cells (nTreg) from
DA rats cultured for 3 days with DA (auto) or PVG (allo) stimulators in the
presence of rIL-2, rIL-4, or no cytokines. The CD25+ population was
re-enriched to remove stimulator cells. il-12rβ2 was increased in
CD4+CD25+ T cells cultured with rIL-2 and alloantigen to induce Ts1 cells
and to a lesser extent with autoantigen. There was no il-12rβ2 expression in
nTreg cultured with alloantigen alone with no cytokine as well as those
cultured with rIL-4 and auto- or alloantigen. There was no expression of il-2,
confirming no Th1 induction after culture with rIL-2, ifngr was induced, but
not with rIL-4, as described (8) (data not shown). One of three experiments
with similar results. (C) Proliferation of Ts1 cells re-cultured with alloantigen
and rIL-12p70. nTreg were simulated with PVG stimulators and rIL-2 for
4 days to produce Ts1 cells that were washed and then re-stimulated for
3 days with PVG stimulators alone or with rIL-12p70, rIL-12p40, rIL-2, or
control (supernatant from non-transfected CHO-K). Only rIL-2 (p< 0.05) and
rIL-12p70 (p<0.05) induced significant proliferation compared to controls,
with no cytokine or with supernatant from non-transfected CHO-K cells.
This induction of proliferation by rIL-12p70 demonstrated a functional
significance of il-12rβ2 expression by Ts1 cells.
ifn-γ were induced in Ts1 cells re-cultured with rIL-12p70 alone
but not with rIL-2 alone or with both rIL-2 and rIL-12p70, con-
sistent with a Th1-like Treg phenotype. The presence of rIL-2 in
re-culture prevented induction of Th1-like Treg by rIL-12p70, as
there was no induction of t-bet or ifn-γ mRNA.
Ts1 cells express il-5 (2), and this expression was enhanced by
culture with rIL-12p70 alone, but not in cultures with rIL-2.
FIGURE 3 | Examination of phenotype and suppressive ability ofTs1
cells re-cultured with rIL-12p70 alone or in combination with IL-2. Ts1
cells were washed and re-cultured with alloantigen and either rIL-2 alone,
rIL-12p70 alone, or both rIL-2 and rIL-12p70 for 4 days before examination of:
(A) CD25 and Foxp3 expression. All three cultures showed that a large
proportion of cells were CD25high and 70–80% expressed Foxp3.
(B) Suppressive ability. Cells from all three cultures were tested for ability
to suppress naive CD4+CD25− T cell proliferation in MLC against PVG (top
panel) or third party Lewis (lower panel) stimulator cells. A constant number
(1×105) of naïve CD4+CD25− T cells were cultured with serial dilutions of
re-cultured Ts1 cells. Ts1 re-cultured with PVG alloantigen and either
rIL-12p70 (•) or rIL-2 and rIL-12p70 (4) had greater suppression compared to
those re-stimulated with IL-2 alone (◦). Proliferation was suppressed to or
below background levels observed with naïve CD4+CD25− T cells cultured
alone (5.0± 1.2×103 cpm) or with syngeneic DA stimulator cells
(5.1±2.0 cpm). Ts1 re-cultured with rIL-12p70 showed significant
suppression at all dilutions (p<0.001). Ts1 cells re-cultured with alloantigen
(Continued)
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FIGURE 3 | Continued
and both rIL-2 and rIL-12p70 suppressed at dilutions to 1:256 (p<0.0001).
Ts1 cells re-cultured with rIL-2 and specific alloantigen, only suppressed to
1:32 (p<0.001) showing no enhancement in suppressive ability of Ts1 cells
that suppressed at 1:32–1:64 ratio to naive CD4+CD25− T cells, as
described (8). Suppression of CD4+CD25− T cells response to third party
Lewis alloantigen was similar to specific donor PVG. Thus, re-culture of Ts1
cells with specific alloantigen with rIL-12p70 increased their potency to
suppress in vitro, whereas re-culture of Ts1 with rIL-2 and alloantigen did
not. Similar results in two other experiments.
Thus, re-culture of Ts1 cells with rIL-12p70 in the absence of
rIL-2, induced a Th1-like Treg, which expressed more il-12rβ2, t-
bet, ifn-γ, and il-5 while retaining a Treg phenotype by expression
of foxp3 and no expression of il-2. Ifngr expression was less. They
thus retained the Ts1 phenotype in that they expressed foxp3, ifngr,
and il-5 and were induced to express t-bet and ifn-γ. Re-culture
of Ts1 with rIL-2 alone retained the Ts1 phenotype of foxp3, ifngr,
il-12rβ2, and some il-5. Re-culture with both rIL-2 and rIL-12p70
led to loss of Ts1 phenotype and did not induce a Th1-like Treg
phenotype, albeit they continued to express foxp3 and did not
express il-2.
EXAMINATION OF IFN-γ OR iNOS AS MEDIATORS OF rIL-12p70 EFFECT
ON Ts1
IL-12p70 prevents immune injury by induction of IFN-γ, which
in turn induces iNOS leading to production of NO (29). Here, we
found that re-culture of Ts1 with rIL-12p70 alone induced Th1-
like Treg expressing ifn-γ. To examine if IFN-γ or iNOS played a
role in the induction of Th1-like Treg, we compared Ts1 cells re-
cultured with rIL-12p70 alone to those cultured with rIL-12p70
and either anti-IFN-γ antibody to block IFN-γ or L-NIL to inhibit
iNOS. Post-culture, all three cell populations were >95% CD25+
and 75–81% Foxp3+ similar to the starting naïve nTreg and Ts1
cells (Figure 5A).
Cells from all three cultures were subjected to suppressor cell
assay as in previous section for their ability to suppress prolifera-
tion of naïve DA CD4+ T cells to PVG (Figure 5B) and to Lewis
alloantigen (results not shown). Proliferation of CD4+ T cells was
suppressed with re-cultured Ts1 cells from all three cultures to
levels similar to background proliferation. The proliferation was
significantly less than the control response of naïve CD4+ T cells
to PVG with no stimulators or no Treg added. These results sug-
gested that rIL-12p70’s induction of Th1-like Treg was not through
induction of IFN-γ or production of nitric oxide by iNOS.
CAPACITY OF IL-12p70 TO INDUCE Treg THAT SUPPRESS ALLOGRAFT
REJECTION
The aim of this study was to induce potent alloantigen-specific
Treg in vitro that alone could suppress allograft rejection in vivo
without any other immunosuppression. Ts1 cells were re-cultured
with rIL-12p70 and PVG alloantigen for 4 days to generate Th1-
like Treg. 5× 106 of these Th1-like Treg cells were transferred to
normal DA rats transplanted with PVG or Lewis heterotopic car-
diac allografts without any immunosuppression. The Treg were
given 3 days after transplant, at a time where the host will have acti-
vated T cells against the graft and there would be induction of IL-
12. We reasoned that the Th1-like Treg would need IL-12 to survive
FIGURE 4 | Expression of transcription factor, cytokine, and cytokine
receptor mRNA inTs1 cells re-cultured with alloantigen and either
rIL-2, rIL-12p70, or both rIL-2 and rIL-12p70. Ts1 cells re-cultured with
alloantigen and either rIL-12p70 alone or rIL-2 and rIL-12p70 had high
expression of foxp3 suggesting cells in all cultures were Treg. il-12rβ2 levels
were preserved in cultures with rIL-2 alone and rIL-12p70 alone but not
those cultured with both rIL-2 and rIL-12p70. ifngr expression was enhanced
with rIL-2, and was sustained with rIL-12p70 but not with both rIL-2 and
rIL-12p70. il-5 expression was increased with rIL-12p70 but waned with rIL-2
and was lost with rIL-2 and rIL-12p70. Induction of t-bet, the Th1
transcription factor, and ifn-γ occurred after re-culture with rIL-12p70 alone,
and not after re-culture with rIL-2 or both rIL-2 and rIL-12p70. Thus, Ts1 cells
re-cultured with rIL-12p70 alone developed a Th1-like Treg phenotype, while
retaining foxp3 expression and the CD4+CD25+Foxp3+ phenotype.
Re-culture of Ts1 cells with rIL-2 retained the Ts1 phenotype. Re-culture of
Ts1 cells with both rIL-2 and rIL-12p70 led to loss of the Ts1 phenotype and
did not induce a Th1-like Treg phenotype.
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FIGURE 5 | Blocking IFN-γ or iNOS had no effect on alloantigen/
IL-12p70 mediated enhancement of suppressive ability ofTs1 cells:Ts1
cells generated by culture of nTreg with PVG alloantigen and rIL-2 for
3 days were re-cultured with PVG alloantigen and either rIL-12p70
alone, rIL-12p70, and anti-IFN-γ (DB-1) or rIL-12p70 and L-NIL. After
culture (A) Foxp3 expression was maintained in all cultures with 75–81%
expressing both CD25 and Foxp3. The starting nTreg and Ts1 populations
had 70–80% Foxp3+ with nearly all were CD4+CD25+. (B) Blocking either
IFN-γ or iNOS had no effect on the capacity of Ts1 cells re-cultured with
rIL-12p70 and PVG stimulators to suppress naïve CD4+ T cell proliferation in
MLC against specific PVG stimulators as measured by 3H-thymidine
incorporation (cpm ×103). MLC was significantly suppressed to or below
background proliferation of control CD4+ T cells with no allogeneic
stimulator (1.69+ 1.2×103 cpm). Ts1 cells re-cultured with specific PVG
stimulators and rIL-12p70 alone (•) had significantly suppressed proliferation
of CD4+ T cells to PVG stimulators at all ratios of 1:4 through to 1:1024
(p<0.02); for Ts1 cells re-cultured with rIL-12p70 and anti-IFN-γ (◦),
p<0.015 to 1:512, and p= 0.02 at 1:1024. Ts1 re-cultured with rIL-12p70
and L-NIL (4) significant differences were from 1:4 through to 1:512;
p<0.004 except for 1:64 and 1:128. These results suggested rIL-12p70
directly acted on Ts1 cells, not via induction of IFN-γ and iNOS.
and promote their further expansion. These Th1-like Treg signifi-
cantly delayed PVG cardiac allograft rejection (12–70 days, median
46 days) compared to normal rejection of 7–10 days (p< 0.01) in
this model. However, these Th1-like Treg activated against PVG
alloantigen had no effect on third party Lewis graft rejection of
9–10 days, which was the same as control normal rejection time of
8–11 days (Figure 6). Ts1 cells re-cultured with rIL-2 and PVG
alloantigen for another 4 days, did not delay rejection of PVG
heterotopic cardiac allografts as all grafts were rejected in 7–8 days.
Adult rats have approximately 5× 108 peripheral CD4+ T cells,
thus suppression by Th1-like Treg, occurred at a ratio of 1:100
of Treg to effector CD4+ T cells. 5× 106 activated CD4+CD25+
FIGURE 6 | In vivo suppression of allograft rejection byTs1 cells
re-cultured with PVG stimulators and rIL-12p70. Ts1 cells generated by
culture of CD4+CD25+ T cells with PVG alloantigen and rIL-2 for 3 days were
re-cultured with rIL-12p70 and PVG alloantigen for 4 days to produce Th1-like
Treg (•). 5×106 of the Th1-like Treg were given 3 days after grafting, as we
expected by that time the rejection response producing IL-2, IL-12p70, and
IFN-γ would be induced in the host, as described (32). These delayed PVG
(top panel) but not third party Lewis (bottom panel) allograft rejection
compared to normal rejection controls (◦) (n=5/group) (p<0.01). In
comparison, 5×106 Ts1 cells that had been re-cultured with rIL-2 and PVG
for 4 days (N) did not delay rejection (n=4), this demonstrated re-culture of
Ts1 cells with rIL-12p70 was required to induce potent alloantigen-specific
Treg that could suppress rejection.
Treg given i.v. would not have markedly increased the peripheral
CD4+CD25+ T cell pool, which is 3–5× 107 (4, 8, 9).
DISCUSSION
These results support our hypothesis that activation of nTreg to
alloantigen-specific Treg occurs in parallel with effector T cell acti-
vation (1, 2). With Th1 responses, initial activation is dependent
on IL-2, the early Th1 cytokine. As IL-2 production wanes, the
activated antigen-specific Treg appear to express ifngr and il-12rβ2
suggesting Th1 cytokines IFN-γ and IL-12p70, whose expression
persists after expression of IL-2 waned, may be required for sur-
vival of alloantigen-specific Treg (Figure 7). In this study, we
identified that nTreg that had been activated by rIL-2 and alloanti-
gen, that we describe as Ts1 (2), had their in vitro suppressive
potency enhanced by further culture with rIL-12p70 and specific
alloantigen. Indeed, Ts1 cells re-cultured with rIL-12p70 and spe-
cific alloantigen suppressed proliferation of naïve CD4+ T cells
in MLC at a ratio of <1:1024. This suppression in vitro was not
alloantigen-specific, however.
These Ts1 cells re-cultured with rIL-12p70 were potent antigen-
specific suppressor cells in vivo that significantly delayed fully
allogeneic specific donor but not third party donor heart graft
rejection in normal hosts that received no other immunosuppres-
sive treatment. DA rats can be readily induced to become tolerant
to PVG (3, 35, 37, 39) and Lewis (36) organ allografts and the
rate of induction of tolerance is similar. The same Th1-like Treg
that suppressed PVG allograft rejection did not delay rejection of
Lewis allograft, suggesting this was alloantigen-specific suppres-
sion. Thus, Th1-like Treg suppressed at a ratio of 1:100 or less to
the host’s naïve CD4+CD25− T cells.
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FIGURE 7 | Proposed pathway for activation/proliferation of
alloantigen-specific nTreg and comparison with the non-antigen driven
proliferation of nTreg that do not have aTCR specific for the antigen.
rIL-2, without antigen, induced proliferation of nTreg, which retain the
characteristics of nTreg. In presence of antigen and rIL-2, nTreg with TCR for
the stimulating antigen are first induced to express aTs1 phenotype, including
expression of ifngr, il-12rβ2, foxp3, and il-5. Stimulation of these Ts1 cells with
alloantigen and rIL-12p70 in the absence of rIL-2, induced Th1-like Treg that
retain the Ts1 phenotype, but in addition express t-bet and ifn-γ and no il-2.
These have enhanced capacity to suppress in vitro and in vivo at lower ratios
to effector CD4+ T cells, than nTreg (1:100 vs. 1:1) and Ts1 [1:100 vs. 1:10 (2)].
Thus, inflammatory Th1 cytokines drive induction of alloantigen-specific Treg;
the first step is induction of alloantigen-specific Ts1 cells by the early Th1
cytokine IL-2; the second step is induced by rIL-12p70 only after IL-2
production wanes. rIL-12p70 induces Th1-like Treg that express both t-bet and
foxp3 as well as ifn-γ, ifngr, and il-5. Adapted from Figure 1 in Hall et al. (1).
Our studies used a heterogenous population of nTreg, that
were 99% CD4+ and 98% CD25+ but only 70–80% Foxp3+.
This is a standard preparation for murine studies. We used this
population as we were examining practical ways of preparing
antigen-specific Treg for therapy. The partial contribution of the
CD4+CD25+Foxp3− population cannot be excluded, however
there was no induction of il-2, suggesting Th1 cells were not
activated.
These findings demonstrated that IL-12p70 is an important
additional cytokine for the induction and full function of Treg
of the Ts1 lineage, as has been suggested by others (21, 23) and
reviewed in Hall et al. (1). Although proliferation and yield from
cultures of Ts1 cells with rIL-12p70 alone was less than with
rIL-2 alone the Th1-like Treg were more potent and thereby com-
pensated for lower yield. As nTreg expressing TCR for specific
antigen are a minor fraction of the whole nTreg population, any
expansion of antigen-specific Treg will be associated with lower
rates of proliferation and lower yields, than polyclonal activation
with rIL-2.
We initiated these studies as the bioassay for IL-12p70 mea-
sures increased proliferation of IL-2 dependent T cells (38). We
found rIL-12p70 but not rIL-12p40 promoted proliferation of
rIL-2 alloactivated CD4+CD25+ nTreg. In previous studies, we
described Ts1 cells express ifngr, a receptor for a late Th1 cytokine
(2) and here we show that they also induced il-12rβ2 expression.
Ts2 cells generated by culture of nTreg with rIL-4 and alloantigen
did not express il-12rβ2 or ifngr, but expressed il-5rα, the recep-
tor for the late Th2 cytokine IL-5 (2). rIL-12p70 in cultures of
nTreg with rIL-2 and alloantigen enhanced their proliferation, but
had no effect on nTreg in cultures with IL-4 and alloantigen. The
Ts1 cells induced by alloantigen and rIL-2 proliferated when re-
cultured with rIL-12p70 alone, demonstrating that IL-12Rβ2 was
functional. In the presence of rIL-12p70, Ts1 cells were activated
to Th1-like Treg expressing T-bet, foxp3, ifn-γ, ifngr, il-12rβ2, il-5
but no il-2. This Th1-like Treg population displayed an enhanced
ability to suppress the proliferation of naïve CD4+CD25− T cells
at a ratio of <1:1000 in vitro and <1:100 in vivo.
These findings extend our previous study that identified two
separate lineages of Treg induced from nTreg by activation with
alloantigen and either rIL-2 or rIL-4 (2). These strengthen our
hypothesis that the initial activation of nTreg depends upon the
early Th1 and Th2 cytokines, IL-2 or IL-4 to induce Ts1 and Ts2
cells, respectively (2). Within days, Ts1 cells become dependent for
their growth and survival on other Th1 cytokines that are produced
late in a Th1 response, as illustrated in Figure 7. In the case of Ts1,
these appear to be IFN-γ and IL-12p70. This model proposes that
development of nTreg into antigen-specific Treg is an inbuilt reg-
ulatory mechanism that is activated in parallel with Th1 responses
(1). Further, this study identified a second step for the activation of
potent alloantigen-specific Treg in presence of IL-12p70 alone that
may occur when IL-2 production wanes. Thus, the induction of
highly potent alloantigen-specific Treg during a Th1 response ini-
tially requires IL-2, but later may become dependent on IL-12p70
and possibly IFN-γ as reviewed in Ref. (1).
In our studies, it cannot be excluded that rIL-12p70’s effect is
indirect, by activating a minority Th1 population in the cultures.
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This was manifest by the induction of t-bet and ifn-γ within the
cells re-cultured with rIL-12p70 alone. It is possible that release
of IFN-γ during a Th1 response activated by rIL-12p70, activated
Ts1 cells by the IFNGR they express. An alternate possibility is that
rIL-12p70 induced t-bet and ifn-γ in the Treg so they could pro-
duce IFN-γ to promote their own function and growth. Blocking
anti-IFN-γ mAb did not prevent rIL-12p70 inducing highly sup-
pressive Treg suggesting induction of Th1-like Treg did not depend
on IFN-γ.
Many of the anti-inflammatory effects of IL-12p70 are attrib-
uted to production of IFN-γ that in turn induces iNOS to produce
nitric oxide (29). Our studies show that any production of nitric
oxide by iNOS is not essential for Th1-like Treg development
in vitro. In other studies, we found the same concentration of
L-NIL and anti-IFN-γ, enhanced proliferation of CD4+CD25−
T cells by blocking induction of iNOS and NO (9). Thus, in the
current study L-NIL and IFN-γ would have been blocked, sup-
porting the notion that IL-12p70 directly acts via the IL-12Rβ2
on Ts1 cells to induce proliferation and activation to more potent
Th1-like Treg.
These findings are supported by recent reports of induction
of Th1-like Treg during Th1 responses (23). These Th1-like Treg
can be induced by IFN-γ or IL-12p70, and express t-bet, stat1
and ifn-γ, as well as foxp3. Our studies demonstrated that the
removal of rIL-2, and continued culture of Ts1 cells with rIL-
12p70 induced a Th1-like Treg (Figure 7) (23). In man, Th1-like
Treg have been described in patients with multiple sclerosis (26)
and renal transplants (27).
IL-12p70 is a heterodimer composed of p35 and p40 and is a
pro-inflammatory cytokine that enhances Th1 (40, 41), cytotoxic
CD8+ T (42), and NK (43) cell responses by increasing IFN-γ
production (44). IL-12p70 also promotes proliferation of IL-2
dependent T cells and enhances expression of CD25 on CD4+
Th1 cells (45) and clones (46) and on activated CD8+ T cells (42)
IL-12p70 acts by binding to a high affinity receptor, which is a
heterodimer of IL-12Rβ1 and IL-12Rβ2 (47). Resting T cells do
not express high affinity il-12rβ2 (48), but both chains are up-
regulated by TCR and CD28 stimulation, as well as by IL-2 and
IFN-γ. IL-4 and IL-10 decrease expression of il-12rβ2. Thus, in vivo
where there are CD4+ and CD8+ T effectors, the effects of IL-
12p70 may be more complex (49) than observed here with isolated
CD4+CD25+ Treg. Our results suggest that CD4+CD25+Foxp3+
Treg activated by antigen and IL-2, like activated effector T cells,
express il-12rβ2 and respond to IL-12p70.
Because IL-12p70 promotes induction of Th1 and cytotoxic
T cell responses, it was predicted to play a key role in amplify-
ing rejection and GVHD (50). Paradoxically, treatment with one
dose of IL-12p70 at the time of bone marrow transfer inhibits
fully allogeneic GVHD (51). Prevention of GVHD by rIL-12p70 is
dependent on donor IFN-γ (52) and acts via Fas to inhibit donor
T cell expansion (53). IL-12p70 treatment delays allograft rejec-
tion (29) and inhibits autoimmunity including uveitis (54) and
EAE (22). The protective effects of IL-12p70 are associated with
induction of ifn-γ and inos (54). Blocking IFN-γ or iNOS with
L-NIL prevents IL-12p70 prolonging graft rejection (29). How-
ever, these studies did not examine any effect of IL-12p70 on Treg
activation.
Further evidence that IL-12p70 can control autoimmune
inflammation comes from enhanced autoimmunity in IL-
12p35−/− mice (55), IL-12Rβ2−/− (56), IFN-γ−/− (57), and
IFNGR−/− (58) mice compared to wild-type control mice.
Our study confirmed the role of IL-12p70 in induction of Th1-
like Treg (21, 23) and demonstrated another mechanism by which
IL-12p70 may down-regulate immune responses.
Current preclinical and early clinical studies use nTreg that have
been expanded in numbers by repeated culture of nTreg with IL-2
and mAb to CD3 and in some studies to CD28. However, these
cells remain nTreg phenotype and are required at a physiological
ratio of >1:4, and usually 1:1 to effector cells to suppress GVHD
(11, 14) and allograft rejection (8).
Our study identifies a way to expand, within a week, highly
potent alloantigen-specific Treg that can suppress allograft rejec-
tion. We hypothesize that nTreg with TCR for the specific alloanti-
gen express ifngr (2) and il-12rβ2 (Figure 7) and have increased
potency of suppression (2). At the same time, there is IL-2 induced
polyclonal expansion of nTreg, which remain nTreg and are not
induced to express ifngr and il-12rβ2, as illustrated in Figure 7.
To our knowledge, this is the first description of a Treg with
antigen-specificity that can delay fully allogeneic graft rejection in
unmodified recipients. The relatively short culture period required
to induce Th1-like Treg and the small number required to suppress
fully allogeneic graft rejection provide potential for generation of
Th1-like Treg in vitro for clinical use.
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